Effect of the angiotensin ii receptor blocker valsartan on cardiac hypertrophy and myocardial histone deacetylase expression in rats with aortic constriction

Experimental and Therapeutic Medicine

Volumn 9, Issue 6, 2015, Pages 2225-2228

  Xu, Wei Ping ^a   Yao, Tong Qing ^a   Jiang, Yi Bo ^b   Zhang, Mao Zhen ^a   Wang, Yue Peng ^a   Yu, Ying ^a   Li, Jing Xiang ^a   Li, Yi Gang ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TAIXING PEOPLE'S HOSPITAL   (China)

Author keywords

Angiotensin II receptor blockers; Cardiac hypertrophy; Histone deacetylases

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 9; UNCLASSIFIED DRUG; VALSARTAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BODY WEIGHT; CELL NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; IMMUNORADIOMETRIC ASSAY; MALE; MRNA EXPRESSION ASSAY; NONHUMAN; PLETHYSMOGRAPHY; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE;

EID: 84928233053     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2374     Document Type: Article

References (23)

1. Zhang CL, McKinsey TA, Chang S, et al: Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110: 479-488, 2002.
2. Berridge MJ: Remodelling Ca2+ signalling systems and cardiac hypertrophy. Biochem Soc Trans 34: 228-231, 2006.
3. Bisping E, Ikeda S, et al: Transcription factor GATA4 is activated but not required for insulin-like growth factor 1 (IGF1)-induced cardiac hypertrophy. J Biol Chem 287: 9827-9834, 2012.
4. Toko H, Minamino T and Komuro I: Role of heat shock transcriptional factor 1 and heat shock proteins in cardiac hypertrophy. Trends Cardiovasc Med 18: 88-93, 2008.
5. Xie M and Hill JA: HDAC-dependent ventricular remodeling. Trends Cardiovasc Med 23: 229-235, 2013.
6. Di Marcotullio L, Canettieri G, Infante P, et al: Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer. Biochim Biophys Acta 1815: 241-252, 2011.
7. Agalioti T, Chen G and Thanos D: Deciphering the transcriptional histone acetylation code for a human gene. Cell 111: 381-392, 2002.
8. Hang CT, Yang J, Han P, et al: Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 466: 62-67, 2010.
9. Pedram A, Razandi M, Narayanan R, et al: Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell 24: 3805-3818, 2013.
10. Kee HJ, Sohn IS, Nam KI, et al: Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113: 51-59, 2006.
11. Prisant LM: Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents. Am J Med 121 (8 Suppl): S8-S15, 2008.
12. Shimada YJ, Passeri JJ, Baggish AL, et al: Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail 1: 480-487, 2013.
13. Li L, Zhou N, Gong H, et al: Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. Hypertens Res 33: 1289-1297, 2010.
14. Gao S, Long CL, Wang RH, et al: K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res 83: 444-456, 2009.
15. Lovenberg W: Animal models for hypertension research. Prog Clin Biol Res 229: 225-240, 1987.
16. Del Ry S, Clerico A, Giannessi D, et al: Measurement of brain natriuretic peptide in plasma samples and cardiac tissue extracts by means of an immunoradiometric assay method. Scand J Clin Lab Invest 60: 81-90, 2000.
17. Wang N, Frank GD, Ding R, et al: Promyelocytic leukemia zinc finger protein activates GATA4 transcription and mediates cardiac hypertrophic signaling from angiotensin II receptor 2. PLoS One 7: e35632, 2012.
18. Colussi C, Illi B, Rosati J, et al: Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacol Res 62: 3-10, 2010.
19. Chu CH, Lo JF, Hu WS, et al: Histone acetylation is essential for ANG-II-induced IGF-IIR gene expression in H9c2 cardiomyoblast cells and pathologically hypertensive rat heart. J Cell Physiol 227: 259-268, 2012.
20. Eom GH, Nam YS, Oh JG, et al: Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy. Circ Res 114: 1133-1143, 2014.
21. Greco TM, Yu F, Guise AJ and Cristea IM: Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation. Mol Cell Proteomics 10: M110.004317, 2011.
22. Nader L, Lahoud L, Chouery E, et al: B-type natriuretic peptide receptors in hypertrophied adult rat cardiomyocytes. Ann Cardiol Angeiol (Paris) 59: 20-24, 2010.
23. Ito H, Hiroe M, Hirata Y, et al: Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload 89: 2198-2203, 1994.